Long-term treatment of bipolar disorder: How should we use lithium salts?;Trattamento a lungo termine del disturbo bipolare: Quale impiego dei sali di litio nella pratica clinica?

Rivista di Psichiatria

Volumn 47, Issue 6, 2012, Pages 515-526

  Del Grande, Claudia ^a   Muti, Matteo ^a   Musetti, Laura ^a   Pergentini, Irene ^a   Corsi, Martina ^a   Turri, Milo ^a   Soldani, Ilaria ^a   Corsini, Giovanni Umberto ^a   Dell'Osso, Liliana ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bipolar disorder; Lithium salts; Long term treatment

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM SALT;

ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL PRACTICE; DISEASE COURSE; DRUG BLOOD LEVEL; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; STRUCTURED INTERVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DAY CARE; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, PSYCHIATRIC; HUMANS; LITHIUM CARBONATE; LONG-TERM CARE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUESTIONNAIRES; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871576390     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: 10.1708/1183.13095     Document Type: Article

References (83)

1. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002; 359: 241-7. (Pubitemid 34113827)
2. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57-63.
3. Akiskal HS. The bipolar spectrum: new concepts in classification and diagnosis. In: Grinspoon L (ed). Psychiatry Update: The American Psychiatric Association Annual Review, Vol II. Washington, DC: American Psychiatric Press, 1983.
4. Frank E, Cassano GB, Shear MK, et al. The spectrum model: a more coherent approach to the complexity of psychiatric symptomatology. CNS Spectr 1998; 3: 23-34. (Pubitemid 29122693)
5. Akiskal HS. Classification, diagnosis and boundaries of bipolar disorders. In: Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N (eds). Bipolar Disorder. London: John Wiley & Sons, 2002.
6. Cassano GB, Akiskal HS, Savino M, Musetti L, Perugi G, Soriani A. Proposed subtypes of bipolar II disorder: with hypomanic episodes and/or with hyperthymic temperament. J Affect Disord 1992; 26: 127-40.
7. Cassano GB, Dell'Osso L, Frank E, et al. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord 1999; 54: 319-28. (Pubitemid 29329443)
8. Dell'Osso L, Armani A, Rucci P, et al. Measuring mood spectrum: comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. Compr Psychiatry 2002; 43: 69-73. (Pubitemid 34056279)
9. Pini S, De Queiroz V, Dell'Osso L, et al. Cross-sectional similarities and differences between schizophrenia, schizoaffective disorder and mania or mixed mania with mood-incongruent psychotic features. Eur Psychiatry 2004; 19: 8-14. (Pubitemid 38210423)
10. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42. (Pubitemid 27212192)
11. WHO. The global burden of disease: 2004 update. WHO, Geneva, 2008.
12. Hirschfeld RM, Lewis L, Vornik LA. Perception and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64: 161-74. (Pubitemid 36268319)
13. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-6. (Pubitemid 32205199)
14. Dell'Osso L, Pini S, Tundo A, Sarno N, Musetti L, Cassano GB. Clinical characteristics of mania, mixed mania and bipolar depression with psychotic features. Bipolar Disord 2000; 4: 315-22.
15. Dell'Osso L, Pini S, Cassano GB, et al. Insight into illness in patients with mania, mixed mania, bipolar depression and major depression with psychotic features. Bipolar Disord 2002; 4: 315-22.
16. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12- month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007; 64: 543-52. (Pubitemid 46718287)
17. Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. J Clin Psychiatry 2008; 69 (suppl 3): 11-9.
18. Akiskal HS. The Scope of Bipolar Disorders. In: Akiskal HS, Tohen M (eds). Bipolar psychopharmacotherapy: caring for the patient, Second Edition. London: John Wiley & Sons, 2011.
19. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002; 63 (suppl 10): 5-12. (Pubitemid 35155102)
20. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-22. (Pubitemid 38419270)
21. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression, Second Edition. New York: Oxford University Press, 2007.
22. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (suppl 4): 1-50.
23. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5: 120-35. (Pubitemid 44121706)
24. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-88.
25. NICE clinical guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute of Health and Clinical Excellence, update 2009.
26. Yatham LN, Kennedy SH, Shaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-55.
27. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10: 59-75. (Pubitemid 34263977)
28. Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord 2009; 11(suppl 2): 77-83.
29. Grof P, Müller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord 2009; 11 (suppl 2): 10-9.
30. Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use? Br J Psychiatry 2007; 191: 474-6. (Pubitemid 350273206)
31. Salvi V, Cat Berro A, Bechon E, Bogetto F, Maina G. Lithium and anticonvulsants in the treatment of mania and in the prophylaxis of recurrences. Riv Psichiatr 2011; 46: 172-81.
32. Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007; 11: 1-226.
33. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412. (Pubitemid 46876306)
34. Bartalena L, Pellegrini L, Meschi M, et al. Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Res 1990; 34: 13-7. (Pubitemid 20370912)
35. Krüger S, Young LT, Bräunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord 2005; 7: 205-15. (Pubitemid 40789904)
36. Vieta E. The treatment of mixed states and the risk of switching to depression. Eur Psychiatry 2005; 20: 96-100. (Pubitemid 40409933)
37. Fenn HH, Robinson D, Luby V, et al. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996; 153: 711-3. (Pubitemid 26133628)
38. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159: 1005-10. (Pubitemid 34586947)
39. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-19. (Pubitemid 41428610)
40. Baldessarini RJ, Tondo L, Davis P, Pompili L, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-39. (Pubitemid 44567144)
41. Sondergard L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorder and risk of suicide. Bipolar Disord 2008; 10: 87-94.
42. Fountoulakis KN, Vieta E, Bouras C, et al. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol 2008; 11: 269-87. (Pubitemid 351231818)
43. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005; 19: 20-2. (Pubitemid 40488659)
44. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: a preliminary study. Prog NeuroPsychopharmacol Biol Psychiatry 2006; 30: 1125-8. (Pubitemid 43928235)
45. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-60. (Pubitemid 46580688)
46. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009; 11 (suppl 2): 92-109.
47. Yucel K, McKinnon MC, Taylor VH, et al. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology 2007; 195: 357-67. (Pubitemid 350160270)
48. Philips ML, Travis MJ, Fagiolini A, Kupfer D. Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 2008; 165: 313-20. (Pubitemid 351704485)
49. Moore GJ, Cortese BM, Glitz DA, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009; 70: 699-705.
50. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Progr NeuroPsychopharmacol Biol Psychiatry 2006; 30: 969-95. (Pubitemid 43928209)
51. Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005; 7: 1-10. (Pubitemid 40227831)
52. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium induced increase in human brain grey matter. Lancet 2000; 356: 1241-2.
53. Silverstone PH, Wu RH, O'Donnel T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003; 18: 73-9. (Pubitemid 36343975)
54. Moore GJ, Bebchuk JM, Parrish JK, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 1999; 156: 1902.
55. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-3. (Pubitemid 37088166)
56. Jope RS, Bijur GN. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol Psychiatry 2002; 7 (suppl 1): 35-45.
57. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004; 29: 32-8. (Pubitemid 38068011)
58. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005; 137: 193-201. (Pubitemid 40798902)
59. Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004; 65: 10-21.
60. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996; 67: 767-77. (Pubitemid 26255675)
61. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-6. (Pubitemid 36999520)
62. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009; 14: 51-9.
63. Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord 2011; 13: 219-26.
64. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 2011; 25: 289-98.
65. Severus WE, Kleindienst N, Seemuller F, Frangou S, Möller HJ, Greil W. What is the optimal serum lithium level in the longterm treatment of bipolar disorder: a review? Bipolar Disord 2008; 10: 231-7. (Pubitemid 351637686)
66. Chen KP, Shen WW, Lu ML. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci 2004; 58: 25-9. (Pubitemid 38200367)
67. Grof P, Schou M. Lithium treatment: focus on long-term prophylaxis. In: Akiskal HS, Tohen M (eds). Bipolar psychopharmacotherapy: caring for the patient, Second Edition. London: John Wiley & Sons, 2011.
68. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-5. (Pubitemid 28037545)
69. Silverstone T, McPherson H, Hunt N, Romans S. How effective is lithium in the prevention of relapse in bipolar disorder? A prospective naturalistic follow-up study. Aust N Z J Psychiatry 1998; 32: 61-6. (Pubitemid 28163918)
70. Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness and efficiency. Br J Psychiatry 1994; 164: 741-64.
71. Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 1997; 95: 361-3. (Pubitemid 27244832)
72. Osher Y, Bersudsky Y, Belmaker RH. The new lithium clinic. Neuropsychobiology 2010; 62: 17-26.
73. Kleindienst N, Severus WE, Möller HJ, Greil W. Is polarity of recurrence related to serum lithium level in patients with bipolar disorder? Eur Arch Psychiatry Clin Neurosci 2005; 255: 72-4. (Pubitemid 40558109)
74. Severus WE, Kleindienst N, Evoniuk G, Bowden C, Möller HJ, Bohus M, et al. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study. J Affect Disord 2009; 115: 466-70.
75. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC, 2000.
76. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) (ed. Biometrics Research). New York: New York State Psychiatric Institute, 2002.
77. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for the use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-71. (Pubitemid 28088172)
78. Guy W. Clinical Global Impression. In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, 1976.
79. Chillotti C, Deiana V, Manchia M, et al. Evaluation of lithium treatment response in Sardinian bipolar patients. Riv Psichiatr 2009; 44: 28-35.
80. Muzina DJ. Pharmacological treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium. Bipolar Disord 2009; 11 (suppl 2): 84-91.
81. Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment: the importance of patient selection. Br J Psychiatry 1993; 163 (suppl 21): 16-9. (Pubitemid 23271365)
82. Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009; 11 (suppl 2): 33-44.
83. Post RM, Altshuler LL. Mood disorders: treatment of bipolar disorders. In: Sadock BJ, Sadock VA, Ruiz P (eds). Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vol I, Ninth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2009.